Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenicriviroc for Liver Fibrosis in NASH (AURORA)
NCT03028740Phase 3Terminated
- Sponsor
- Tobira Therapeutics
- Start
- Apr 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of cenicriviroc in Nonalcoholic steatohepatitis (NASH), sponsored by Tobira Therapeutics. Started Apr 2017; status: terminated.
02
Drugs
cenicriviroc
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03028740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03028740.